Table 2.
Comparison of clinical, demographic, and laboratory characteristics between the patients in the ESA-non-resistant group and ESA-resistant group.
| Variables | Mean ± SD/Med (IQR) | p | |
|---|---|---|---|
| ESA-Non-Resistant Group (%) | ESA-Resistant Group (%) | ||
| Age (years) | 67.00 (51.00–74.00) | 66.00 (41.50–73.50) | 0.919 |
| MAP (mmHg) | 89.91 ± 12.29 | 95.31 ± 14.58 | 0.178 |
| BMI (kg/m2) | 31.13 ± 8.13 | 24.63 ± 4.58 | 0.038 |
| BSA (m2) | 1.99 ± 0.35 | 1.82 ± 0.25 | 0.207 |
| CII | 6.00 (4.00–8.00) | 6.50 (6.00–8.00) | 0.288 |
| HD duration (months) | 50.00 (21.50–111.00) | 36.00 (10.75–87.75) | 0.468 |
| BW gain (kg) | 4.06 ± 2.60 | 4.19 ± 2.86 | 0.870 |
| Kt/V | 1.52 (1.39–1.81) | 1.58 (1.34–1.84) | 0.769 |
| URR (%) | 74.68 (70.31–77.27) | 75.00 (68.43–77.66) | 0.956 |
| Serum iron (μg/dL) | 60.00 (50.00–75.25) | 46.50 (35.75–61.50) | 0.023 |
| Iron saturation (%) | 28.50 (23.75–34.75) | 23.00 (16.25–28.25) | 0.032 |
| TF (mg/dL) | 160.55 ± 26.90 | 160.14 ± 27.53 | 0.962 |
| FER (ng/mL) | 713.36 ± 326.54 | 766.14 ± 436.03 | 0.633 |
| ALP (IU/L) | 84.00 (62.00–109.00) | 85.00 (71.75–122.25) | 0.504 |
| Serum albumin (g/dL) | 3.85 ± 0.36 | 3.73 ± 0.26 | 0.266 |
| Serum Ca (mg/dL) | 8.50 (8.00–9.10) | 8.70 (8.30–9.00) | 0.446 |
| Serum P (mg/dL) | 5.70 (4.50–7.00) | 5.25 (4.58–5.80) | 0.409 |
| CaxP (mg2/dL2) | 46.56 (40.80–62.38) | 46.42 (39.26–53.60) | 0.704 |
| Ca corrected for albumin (md/dL) | 8.70 ± 0.61 | 8.89 ± 0.67 | 0.325 |
| iPTH (pg/mL) | 511.50 (295.25–681.25) | 392.50 (240.25–542.50) | 0.150 |
| Total serum protein (g/dL) | 7.02 ± 0.46 | 6.86 ± 0.44 | 0.280 |
| Potassium (mmol/L) | 4.62 ± 0.52 | 4.65 ± 0.45 | 0.864 |
| Vitamin D (ng/mL) | 33.90 ± 19.13 | 25.61 ± 10.97 | 0.202 |
| Neutrophil-to-lymphocyte ratio | 3.00 (2.00–3.73) | 4.12 (3.75–6.13) | 0.005 |
| Derived neutrophil-to-lymphocyte ratio | 1.72 (1.25–2.28) | 2.14 (1.93–2.36) | 0.105 |
| Platelet-to-lymphocyte ratio | 142.78 (115.79–181.00) | 191.67 (149.23–291.36) | 0.038 |
| Monocyte-to-lymphocyte ratio | 0.44 (0.33–0.57) | 0.62 (0.47–0.90) | 0.024 |
| Platelet-to-monocyte ratio | 333.75 (260.00–410.00) | 326.67 (225.25–450.86) | 0.846 |
| Hemoglobin-to-platelet ratio | 0.05 (0.04–0.06) | 0.04 (0.03–0.05) | 0.153 |
| Hemoglobin-to-lymphocyte ratio | 8.16 ± 3.92 | 9.28 ± 3.39 | 0.345 |
| Neutrophil-to-eosinophil ratio | 14.75 (9.56–28.38) | 23.50 (9.21–32.00) | 0.714 |
| Lymphocyte-to-RBC ratio | 0.47 ± 0.20 | 0.39 ± 0.17 | 0.175 |
| Neutrophil-to-RBC ratio | 1.29 (0.95–1.71) | 1.43 (1.26–1.81) | 0.266 |
| Monocyte-to-RBC ratio | 0.21 ± 0.09 | 0.22 ± 0.10 | 0.565 |
| Neutrophil-to-platelet ratio | 0.02 ± 0.01 | 0.02 ± 0.01 | 0.697 |
| SII | 595.54 (421.24–928.06) | 832.40 (554.85–1599.14) | 0.128 |
| SIRI | 1.77 (1.05–2.70) | 2.68 (1.78–4.23) | 0.059 |
Legend: SD—standard deviation; IQR—interquartile range; ESA—erythropoiesis-stimulating agents; MAP—mean arterial pressure; BMI—body mass index; BSA—body surface area; CII—Charlson comorbidity index; HD—hemodialysis; BW—body weight; Kt/V—fractional urea clearance; URR—urea reduction ratio; TF—transferrin; FER—ferritin; ALP—alkaline phosphatase; Ca—calcium; P—phosphorus; iPTH—intact parathyroid hormone; RBC—red blood cell ratio; SII—systemic immune-inflammation index; SIRI—systemic inflammation response index.